WATERTOWN, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of
RNAi-based therapeutics targeting genetically defined oncology and
inherited rare diseases, announces webcast and conference call
information for its previously announced R&D Update webcast later today,
December 15, 2014, at 4:30 p.m. Eastern Time.
A live webcast of the presentation can be accessed by visiting "Events
& Presentations" in the Investors and Media section on the
Company's website at www.dicerna.com.
An archived replay of the webcast will be available on the Company's
website after the conference.
The call can also be accessed by dialing (855)-453-3834 or (484)
756-4306 (international), and referencing conference ID 42098350 prior
to the start of the call.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on
the discovery and development of innovative treatments for rare,
inherited diseases involving the liver and for cancers that are
genetically defined. The company is using its proprietary RNA
interference (RNAi) technology platform to build a broad pipeline in
these therapeutic areas. In both rare diseases and oncology, Dicerna is
pursuing targets that have been difficult to address using conventional
approaches, but where connections between targets and diseases are well
understood and documented. The company intends to discover, develop and
commercialize novel therapeutics either on its own or in collaboration
with pharmaceutical partners. For more information, please visit www.dicerna.com.
Peter Vozzo, 443-213-0505
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media